Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Camidanlumab Tesirine |
Synonyms | |
Therapy Description |
Camidanlumab Tesirine is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Camidanlumab Tesirine | ADCT-301 | Camidanlumab Tesirine (ADCT-301) is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | non-Hodgkin lymphoma | not applicable | Camidanlumab Tesirine | Phase I | Actionable | In a Phase I trial, Camidanlumab Tesirine treatment resulted in partial response in 15.8% (3/19) in non-Hodgkin lymphoma patients (Blood 2017 130(Suppl 1):1510; NCT02432235). | detail... |
Unknown unknown | Hodgkin's lymphoma | not applicable | Camidanlumab Tesirine | Phase I | Actionable | In a Phase I trial, Camidanlumab Tesirine treatment resulted in an objective response rate of 63.6% (14/22) and a complete response rate of 27.3% (6/22) in Hodgkin's lymphoma patients (Blood 2017 130(Suppl 1):1510; NCT02432235). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03621982 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT02432235 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | Completed | USA | 1 |
NCT04052997 | Phase II | Camidanlumab Tesirine | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | Active, not recruiting | USA | CAN | 9 |